Literature DB >> 18079751

IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.

Caroline Hilmi1, Lionel Larribere, Sandy Giuliano, Karine Bille, Jean-Paul Ortonne, Robert Ballotti, Corine Bertolotto.   

Abstract

IGF1 plays a key role in the development and growth of multiple tumors and in the prevention of apoptosis. In melanoma cells, IGF1 has been shown to mediate resistance to anoikis-induced apoptosis. However, the effect of IGF1 on other proapoptotic stimuli has never been reported. Further, the molecular mechanisms by which IGF1 mediates its prosurvival properties in melanoma cells remain unknown. Here, we demonstrate that IGF1 impairs the onset of tumor necrosis factor-related apoptosis-inducing ligand and staurosporine-induced apoptosis in melanoma cells expressing either wild-type or oncogenic B-Raf. Further, we show that IGF1 inhibits mitochondrial damage that occurs during apoptosis, thereby indicating that IGF1 acts at the level of mitochondria to mediate its antiapoptotic stimuli. Accordingly, IGF1 increases the mRNA levels and protein expression of antiapoptotic members of the BCL2 family--BCL2 and BCL-X(L)--and that of the inhibitor of apoptosis protein, survivin. Further, their specific silencing by small interfering RNA prevents the protective effect of IGF1. These findings therefore delineate the molecular mechanisms by which IGF1 mediates its prosurvival properties and provide a basis for clinical strategies designed to neutralize IGF1 or its target genes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079751     DOI: 10.1038/sj.jid.5701185

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  48 in total

1.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

2.  PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.

Authors:  Ravi S Akundi; Lianteng Zhi; Hansruedi Büeler
Journal:  Neurobiol Dis       Date:  2011-09-16       Impact factor: 5.996

Review 3.  Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors:  József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

4.  MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.

Authors:  Lisa Koetz-Ploch; Douglas Hanniford; Igor Dolgalev; Elena Sokolova; Judy Zhong; Marta Díaz-Martínez; Emily Bernstein; Farbod Darvishian; Keith T Flaherty; Paul B Chapman; Hussein Tawbi; Eva Hernando
Journal:  Pigment Cell Melanoma Res       Date:  2017-04-19       Impact factor: 4.693

5.  Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis.

Authors:  Vladimir N Ivanov; Michael A Partridge; Sarah X L Huang; Tom K Hei
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

6.  A phase II study of gefitinib in patients with metastatic melanoma.

Authors:  Sapna P Patel; Kevin B Kim; Nicholas E Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Victor G Prieto; Menashe Bar-Eli; Maya Zigler; Andrey Dobroff; Yulia Bronstein; Roland L Bassett; Anna G Vardeleon; Agop Y Bedikian
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

7.  Aberrant SIRT6 expression contributes to melanoma growth: Role of the autophagy paradox and IGF-AKT signaling.

Authors:  Liwen Wang; Weinan Guo; Jinyuan Ma; Wei Dai; Lin Liu; Sen Guo; Jiaxi Chen; Huina Wang; Yuqi Yang; Xiuli Yi; Gang Wang; Tianwen Gao; Guannan Zhu; Chunying Li
Journal:  Autophagy       Date:  2017-12-31       Impact factor: 16.016

8.  Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.

Authors:  Anfernee Kai-Wing Tse; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

9.  Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.

Authors:  Josep Tabernero; Sant P Chawla; Hedy Kindler; Karen Reckamp; E Gabriela Chiorean; Nilofer S Azad; A Craig Lockhart; Cheng-Pang Hsu; Nigel F Baker; Francesco Galimi; Pedro Beltran; José Baselga
Journal:  Target Oncol       Date:  2014-05-11       Impact factor: 4.493

10.  Upregulated Expression of CUX1 Correlates with Poor Prognosis in Glioma Patients: a Bioinformatic Analysis.

Authors:  Xiujie Wu; Fan Feng; Chuanchao Yang; Moxuan Zhang; Yanhao Cheng; Yayun Zhao; Yayu Wang; Fengyuan Che; Jian Zhang; Xueyuan Heng
Journal:  J Mol Neurosci       Date:  2019-08-03       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.